[{"indications": "Indications\u00a0prophylaxis of allergic asthma (\n(From Omalizumab: British National Formulary)\nOmalizumab)", "name": "OMALIZUMAB", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "3 Respiratory system", "3.4 Antihistamines, hyposensitisation, and allergic emergencies", "3.4.2 Allergen immunotherapy", "Omalizumab"], "cautions": "Cautions\u00a0autoimmune disease; susceptibility to helminth infection\u2014discontinue if infection does\r\nnot respond to anthelmintic", "side-effects": "Side-effects\u00a0abdominal pain, headache, pyrexia; less\r\ncommonly dyspepsia, nausea, diarrhoea, weight increase, postural\r\nhypotension, flushing, pharyngitis, bronchospasm, cough, syncope,\r\nparaesthesia, dizziness, malaise, influenza-like illness, photosensitivity,\r\nurticaria, rash, pruritus; rarely laryngoedema, parasitic\r\ninfection, antibody formation; also reported arterial\r\nthromboembolic events, Churg-Strauss syndrome (\n(From Omalizumab: British National Formulary)\nChurg-Strauss syndrome has occurred rarely in patients given omalizumab; the reaction is usually associated with the reduction of oral corticosteroid therapy. Churg-Strauss syndrome can present as eosinophilia, vasculitic rash, cardiac complications, worsening pulmonary symptoms, or peripheral neuropathy. Hypersensitivity reactions can also occur immediately following treatment with omalizumab or sometimes more than 24 hours after the first injection.), thrombocytopenia, arthralgia, myalgia, joint swelling, alopecia,\r\nserum sickness (including fever and lymphadenopathy)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129492.htm", "doses": ["By subcutaneous injection, adult and child over\r\n6 years, according to immunoglobulin E concentration and body-weight,\r\nconsult product literature"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid unless essential"}]